Petrelintide
Also known as: ZP-petrelintide, long-acting human amylin analogue, DACRA (dual amylin and calcitonin receptor agonist)
Long-acting amylin analogue / dual amylin and calcitonin receptor agonist (DACRA)
What it is
Petrelintide is an experimental weight-loss drug in clinical development for obesity, being studied as a potential standalone and combination therapy. It works by mimicking amylin, a hormone that signals fullness after eating, to reduce appetite and food intake. Not FDA-approved; Phase 2 trial data published in 2026; in active clinical development.
The scientific side
Petrelintide is a potent, stable, long-acting analogue of human amylin designed to be formulated at approximately neutral pH. It acts as a dual agonist at amylin receptors (AMYR) and calcitonin receptors (CTR). As an amylin-based agent, its pharmacological class promotes satiation through central nervous system mechanisms, slows gastric emptying, and suppresses glucagon secretion — consistent with the class mechanism described for amylin analogues (PMID 42452898; PMID 42586227). Its mechanism of action is described as distinct from incretin-based treatments such as GLP-1 receptor agonists. Development involved optimization of chemical stability while retaining in vitro and in vivo potency.
Class: Long-acting amylin analogue / dual amylin and calcitonin receptor agonist (DACRA)
Administration & storage
- Administration
- Subcutaneous (SC) injection — self-administered once-weekly in phase 2 trial (PMID: 42810355)Subcutaneous (SC) injection — used in both SAD and MAD phase 1 trials (PMID: 42017294)Intravenous (IV) injection — 0.35 mg single dose in SAD phase 1 trial (PMID: 42017294)
- Storage
- No storage conditions for petrelintide are described in the reviewed abstracts.
- Cautions
- Nausea was the most common adverse event, occurring in 20% of petrelintide-treated participants vs 6% with placebo in the phase 2 trial, predominantly during dose escalation; it was largely mild.,Gastrointestinal adverse events (nausea, rare diarrhoea) were the most common TEAEs in phase 1 trials; one participant discontinued treatment due to GI TEAEs.,Vomiting was infrequent in the phase 2 trial (3% petrelintide vs 6% placebo) and was only experienced by the one participant who discontinued in phase 1 (PMID: 42810355; PMID: 42017294).,No serious or severe treatment-emergent adverse events were reported in phase 1 trials; no deaths were reported in the phase 2 trial (PMID: 42017294; PMID: 42810355).,Sterile technique should be maintained for any injectable compound; specific sterility guidance for petrelintide is not provided in the reviewed literature.,Petrelintide is still in clinical development; long-term safety data beyond 42 weeks are not yet available from the reviewed abstracts.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. Phase 2 trial (ZUPREME 1) completed March 2026; described as 'in clinical development'.
Not stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Weight management / obesity treatment Human RCT
- In a 42-week phase 2 RCT (n=485 dosed) in adults with obesity (without T2D), once-weekly subcutaneous petrelintide (1.0–9.0 mg maintenance doses) produced mean bodyweight reductions of −7.9% to −9.8% vs −1.7% with placebo at 28 weeks. Weight continued to decline to week 42, with reductions up to −10.7%. The most common PMID 42810355 Garvey et al. (2026). Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology.
- In two phase 1 randomized, placebo-controlled, double-blind trials (SAD and MAD), subcutaneous petrelintide was well tolerated with no serious or severe TEAEs. The most common TEAEs were mild GI disorders; nausea occurred in 16.7%–33.3% of petrelintide recipients vs 16.7% for placebo in MAD part 2. Petrelintide had a h PMID 42017294 Olsen et al. (2026). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes, Obesity & Metabolism.
- Obesity pharmacotherapy — development as potential combination therapy Animal studies only
- Petrelintide was developed as a potent, stable, long-acting human amylin analogue formulated at approximately neutral pH, enabling potential coformulation with currently marketed drugs. In vitro and in vivo potency were retained through chemical stability optimization. Animal studies (mice, rats, male animals) were use PMID 41217931 Munch et al. (2025). Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. Journal of Medicinal Chemistry.
- Petrelintide, described as undergoing phase II clinical trials, served as the scaffold for structure-activity relationship optimization. In vitro and in vivo studies showed that a derivative (BGM1812) had enhanced agonistic efficacy compared to petrelintide at AMYR and CTR, suggesting petrelintide's agonistic activity PMID 40608546 Zong et al. (2025). Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment. Journal of Medicinal Chemistry.
- Type 2 diabetes and metabolic disease (class-level evidence; petrelintide specifically in obesity-focused trials without T2D requirement) Mixed
- Narrative review identifies petrelintide among long-acting amylin analogues showing strong efficacy as monotherapy in clinical trials for obesity and type 2 diabetes management. Evidence is emerging that long-acting AMYR agonists may show potential therapeutic benefits in fatty liver disease, diabetes-associated kidney PMID 41747885 Bailey, Flatt, Conlon (2026). Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides.
- Review identifies petrelintide as one of several long-acting amylin-based therapies demonstrating clinically meaningful weight loss with generally favorable tolerability profiles in human clinical development as of April 2026. PMID 42452898 Alhazmi & le Roux (2026). Amylin Analogs: The Next Major Class of Weight Loss Therapy. Diabetes, Obesity & Metabolism.
Safety signals
- Nausea: most common adverse event in phase 2 trial (20% petrelintide vs 6% placebo), predominantly mild and occurring during dose escalation; also the most common GI TEAE in phase 1 MAD trial (16.7%–33.3% petrelintide vs 16.7% placebo in MAD part 2). PMID 42810355
- Vomiting: infrequent in phase 2 (3% petrelintide vs 6% placebo); in phase 1, vomiting was only experienced by the one participant who discontinued (PMID: 42017294; PMID: 42810355). PMID 42017294
- Diarrhoea: rare in phase 1 trials; similarly low rates between petrelintide and placebo in phase 2 (7% vs 7%) (PMID: 42810355; PMID: 42017294). PMID 42810355
- Constipation: similarly low rates between petrelintide and placebo in phase 2 (7% vs 4%). PMID 42810355
- One participant discontinued treatment due to GI TEAEs in phase 1 trials; no serious or severe TEAEs were reported in phase 1. PMID 42017294
- Gastrointestinal side effects (especially nausea), similar to those reported for GLP-1R agonists, are described as commonplace during initiation and up-titration of amylin analogues as a class but mostly resolve during continued use (class-level signal). PMID 41747885
Contraindications
- Phase 2 trial (ZUPREME 1) excluded individuals with type 2 diabetes; efficacy and safety in this population have not been established by the reviewed abstracts. PMID 42810355
- Phase 2 trial required BMI ≥30 kg/m², or BMI ≥27 kg/m² with hypertension or dyslipidaemia; safety and efficacy outside these criteria are not addressed in reviewed abstracts. PMID 42810355
Protocol
No community protocol on record. In clinical studies, Petrelintide was dosed at 0.04–2.4 mg (single ascending doses); 0.35 mg intravenous (single dose) Subcutaneous (and one intravenous arm) (PMID 42017294).
All studies (7)
- PMID 42017294 Human RCT
Weight management / obesity treatment - PMID 42810355 Human RCT
Weight management / obesity treatment - PMID 41747885 Mixed
Type 2 diabetes and metabolic disease (class-level evidence; petrelintide specifically in obesity-fo - PMID 42452898 Mixed
Type 2 diabetes and metabolic disease (class-level evidence; petrelintide specifically in obesity-fo - PMID 40608546 Animal studies only
Obesity pharmacotherapy — development as potential combination therapy - PMID 41217931 Animal studies only
Obesity pharmacotherapy — development as potential combination therapy - PMID 42586227
Frequently asked
What is petrelintide and how does it work?
Petrelintide is a long-acting analogue of human amylin, a hormone co-secreted with insulin from pancreatic beta-cells. It acts as a dual agonist at amylin receptors (AMYR) and calcitonin receptors (CTR). As an amylin-based agent, its class promotes satiation through central nervous system mechanisms, slows gastric emptying, and suppresses glucagon secretion. Its mechanism is described as distinct from incretin-based therapies such as GLP-1 receptor agonists. It was engineered for chemical stability and neutral-pH formulation to enable long-acting once-weekly dosing.
How much weight loss can petrelintide produce?
In the ZUPREME 1 phase 2 trial (n=404 on petrelintide), adults with obesity receiving once-weekly subcutaneous petrelintide achieved mean bodyweight reductions of −7.9% to −9.8% versus −1.7% with placebo at 28 weeks, with reductions continuing to up to −10.7% at 42 weeks. In phase 1 multiple ascending dose studies, body weight was reduced by up to 8.6% after 16 weeks. These results are from controlled clinical trials and individual outcomes may differ.
What dose of petrelintide should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: In a phase 2 trial, once-weekly subcutaneous maintenance doses of 1.0–9.0 mg were studied with dose escalation over 42 weeks. In phase 1 trials, doses ranged from 0.04–2.4 mg (single dose) to up to 9.0 mg once-weekly over 16 doses. Petrelintide is still in clinical development and is not approved for prescription use based on the reviewed literature.
What are the side effects of petrelintide?
The most common adverse event in the phase 2 ZUPREME 1 trial was nausea, occurring in 20% of petrelintide participants vs 6% with placebo, predominantly mild and during dose escalation. Vomiting was infrequent (3% vs 6% placebo) and diarrhoea and constipation rates were similar to placebo (~7% each). In phase 1 trials, no serious or severe TEAEs were reported; one participant discontinued due to GI adverse events. No deaths were reported in phase 2.
How is petrelintide administered?
In clinical trials, petrelintide was administered as a once-weekly subcutaneous (under the skin) self-injection. Phase 1 trials also included a single intravenous dose arm for pharmacokinetic assessment. It was developed to be formulated at approximately neutral pH. No commercial formulation or administration instructions are available as it remains in clinical development.
Is petrelintide FDA approved?
Based on the reviewed literature, petrelintide is not yet approved by the FDA. It has completed a phase 2 trial (ZUPREME 1, completed March 2026) and has previously been described as undergoing phase 2 clinical trials (PMID 42810355; PMID 40608546). Regulatory status requires manual verification with current regulatory agency records.
Can I stack petrelintide with semaglutide or other GLP-1 drugs?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Petrelintide has been studied as a monotherapy in phase 1 and phase 2 trials (PMID 42017294; PMID 42810355). Reviews note that amylin-based therapies have a mechanism distinct from GLP-1 receptor agonists and that combination approaches are of interest in the field (PMID 41747885; PMID 42452898), but no petrelintide-specific combination trial data are present in the reviewed abstracts.
How long does petrelintide stay in the body?
In phase 1 pharmacokinetic studies, petrelintide had a half-life of approximately 10 days, was slowly absorbed after subcutaneous injection, and showed steady-state dose proportionality. This long half-life supports once-weekly dosing.
Is petrelintide safe for people with type 2 diabetes?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. For context: the ZUPREME 1 phase 2 trial specifically enrolled adults without type 2 diabetes, so clinical trial data in people with type 2 diabetes are not available in the reviewed abstracts. Review articles note the broader amylin analogue class is being studied for obesity and type 2 diabetes, but petrelintide-specific T2D data are absent from this literature.
Where can I buy petrelintide?
I don't recommend vendors or sources. Please consult a licensed provider. Petrelintide is described in the reviewed literature as being in clinical development and not yet approved for commercial sale (PMID 42810355; PMID 41217931).